Hemodialysis Frequency and the Calcification Propensity of Serum
NCT ID: NCT01975025
Last Updated: 2016-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
17 participants
INTERVENTIONAL
2014-06-30
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients
NCT00485706
FGF-23 and PTH in Hemodialysis Patients
NCT04350944
Use of ETElcalcetidefor pReserving vitamiN K-dependent proteIn activiTY ITAlian Study
NCT06352957
The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density
NCT07171216
Pilot Study to Investigate the Effects of Increased Dialysate Magnesium and Dialysate Bicarbonate on the Calcification Propensity of Serum
NCT02621762
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The serum calcification test has been established and validated by A. Pasch and coworkers, the expertise to perform the necessary statistical analyses is present in the investigator's department, all patient-related procedures necessary for this project are routinely performed in the investigator's department.
Objective
Does short daily hemodialysis strengthen the calcification-inhibitory forces inherent in hemodialysis patient sera, when compared to conventional three-times weekly hemodialysis?
Methods
Serum calcification test
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All study participants
Short daily dialysis for 2 weeks
Short daily dialysis for 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Short daily dialysis for 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Anuria (\<100ml urine per day)
* Written informed consent
Exclusion Criteria
* Significant fistula recirculation (\>15%)
* Infection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baxter Healthcare Corporation
INDUSTRY
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Pasch, PD. Dr. med.
Role: PRINCIPAL_INVESTIGATOR
University Clinic Inselspital Bern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dep. of Nephrology, Hypertension and Clinical Pharmacology, Bern University Hospital
Bern, Canton of Bern, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
146/13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.